The FNIH develops, raises funds and manages collaborative initiatives to support groundbreaking biomedical research.
We engage multiple stakeholders—pharmaceutical and biotech companies, NIH science and policy experts, FDA regulators, university researchers, patient advocacy organizations and individual philanthropists—for a common goal. Working together, we share the risk and the reward of this often complex and costly work. Together, we advance research for discovery, diagnosis, treatment and, ultimately, cures.
The FNIH supports programs in priority areas as diverse as traumatic brain injury, lung cancer, arthritis and Ebola. We currently seek partners and support for the following research programs:
Biomarkers Consortium Projects:
- The Performance of Novel Cardiac Biomarkers in the General U.S. Population (Cardiac Troponin)
- High Definition Single Cell Analysis of Blood and Tissue Biopsies in Patients with Colorectal Cancer undergoing Hepatic Metastasectomy (HD-SCA in CRC)
- Treatments Against Rheumatoid Arthritis and Effect on FDG PET-CT: The TARGET Biomarker Study
- Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Physical Disability